Novel Assay for Rapid Antibody Screening

快速抗体筛选的新方法

• 批准号: 7536704
• 负责人: Scott Allen Monsma
• 金额: $ 21.72万
• 依托单位: PRIMORIGEN BIOSCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7536704
• 关键词: Address; Affinity; Antibodies; Antibody Dissociations; Antibody Formation; Antigens; Beta Cell; Binding; Biological Assay; Cell Differentiation process; Cell Extracts; Cell Line; Cells; Compatible; DNA Sequence; Data; Data Storage and Retrieval; Deposition; Detection; Development; Devices; Differentiation Antigens; Dissociation; Drug Formulations; Effectiveness; Enzyme-Linked Immunosorbent Assay; Equilibrium; Evaluation; Figs - dietary; Funding; Gel; Glass; Government; Human; Hybridomas; Hydrophobic Surfaces; Immunization; Immunoassay; Individual; Insecta; Insulin-Dependent Diabetes Mellitus; Kinetics; Left; Methods; Monoclonal Antibodies; Mus; Nature; Numbers; Persons; Phase; Phase I Clinical Trials; Phase II Clinical Trials; Plastics; Polyesters; Porosity; Protein Array; Protein Binding; Proteins; Protocols documentation; Purpose; Pyroxylin; Reagent; Reference Standards; Reproducibility; Research; Right-On; Sampling; Screening procedure; Slide; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Solutions; Specificity; Speed; Splenocyte; Spottings; Staging; Standards of Weights and Measures; Structure of beta Cell of islet; Surface; System; Systems Analysis; Techniques; Technology; Testing; Time; Transplantation; Western Blotting; Work; base; cost; day; design; expression vector; high throughput analysis; hybridoma production; hydrophilicity; improved; manufacturing process; miniaturize; monoclonal antibody production; novel; research study

DESCRIPTION (provided by applicant): Primorigen Biosciences will use Phase I SBIR funds to develop a frameless, multiplexed, microarray screening system for rapid identification and characterization of antibody matched pairs with appropriate affinity and specificity for target proteins. This system produces improved assay content and dramatically reduces the time and cost of multiplexed microarray development. The core of this new system is Primorigen's novel frameless microarray device for multiplexed analysis that allows testing of 96 (or 384) samples against several binding targets directly on a flat array surface. As a result, dozens of proteins in hundreds of samples can be detected with high precision to generate thousands of data points per experiment, increasing speed of screening. While the new system can be adapted to detect any protein, this Phase I project will focus on detecting human pancreatic beta cell markers useful for characterizing insulin-secreting cell lines that may be candidates to treat or cure Type 1 diabetes. The Phase I project will develop a frameless nitrocellulose assay surface and use the miniaturized array methods to screen and characterize antibodies that detect the target proteins. Phase II will a) validate these assays for commercial use, b) develop manufacturing protocols, and c) apply this system to cell differentiation markers.

描述（由申请人提供）：Primorigen Biosciences将使用第一阶段SBIR资金开发一种无框架、多路复用、微阵列筛选系统，用于快速识别和表征具有适当亲和力和特异性的抗体匹配对的目标蛋白。该系统提高了分析含量，大大减少了多路微阵列开发的时间和成本。这个新系统的核心是Primorigen的新型无框微阵列设备，用于多路分析，可以直接在平面阵列表面上针对几个结合目标测试96（或384）个样品。因此，可以高精度地检测数百个样品中的数十种蛋白质，每次实验产生数千个数据点，提高筛选速度。虽然新系统可以用于检测任何蛋白质，但这个I期项目将专注于检测人类胰腺β细胞标记物，这些标记物有助于表征胰岛素分泌细胞系，可能是治疗或治愈1型糖尿病的候选细胞。第一阶段项目将开发一种无框硝化纤维素检测表面，并使用小型化阵列方法筛选和表征检测目标蛋白的抗体。II期将a)验证这些检测用于商业用途，b)制定制造方案，以及c)将该系统应用于细胞分化标记物。